Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

S Saad

Showing results (501-510 of 531) with videos related to

Pageof 54
Sort By:
Arthritis Care & Research|November 22, 2021
Impact of Distinct Therapies on Antibody Response to SARS-CoV-2 Vaccine in Systemic Lupus ErythematosusEmily F N Yuki, Eduardo F Borba, Sandra G Pasoto, et al.
Journal of Physical Activity & Health|June 8, 2023
No Associations Between Physical Activity and Immunogenicity in SARS-CoV-2 Seropositive Patients With Autoimmune Rheumatic Diseases Prior to and After VaccinationFabiana Infante Smaira, Bruna Caruso Mazzolani, Ítalo Ribeiro Lemes, et al.
Journal of Clinical Rheumatology : Practical Reports on Rheumatic & Musculoskeletal Diseases|March 4, 2025
Disease Safety, Immunogenicity, and Efficacy of Recombinant Herpes Zoster Vaccine (RZV or Shingrix) in Autoimmune Rheumatic Diseases: Launching a Randomized Phase 4 StudyLeonard V K Kupa, Ana Cristina Medeiros-Ribeiro, Nádia E Aikawa, et al.
Annals of the Rheumatic Diseases|February 9, 2022
Distinct impact of DMARD combination and monotherapy in immunogenicity of an inactivated SARS-CoV-2 vaccine in rheumatoid arthritisAna Cristina Medeiros-Ribeiro, Karina Rossi Bonfiglioli, Diogo Souza Domiciano, et al.
Rheumatology (Oxford, England)|October 19, 2021
Systemic autoimmune myopathies: a prospective phase 4 controlled trial of an inactivated virus vaccine against SARS-CoV-2Samuel K Shinjo, Fernando H C de Souza, Isabela B P Borges, et al.
Plos One|November 17, 2011
Immunogenicity and reactogenicity of 2009 influenza A (H1N1) inactivated monovalent non-adjuvanted vaccine in elderly and immunocompromised patientsJoão L Miraglia, Edson Abdala, Paulo M Hoff, et al.
Journal of Applied Physiology (Bethesda, Md. : 1985)|February 10, 2022
Effect of an exercise bout before the booster dose of an inactivated SARS-CoV-2 vaccine on immunogenicity in immunocompromised patientsBruno Gualano, Carla G S Saad, Sofia M Sieczkowska, et al.
Medrxiv : the Preprint Server for Health Sciences|November 22, 2024
Timing of changes in Alzheimer's disease plasma biomarkers as assessed by amyloid and tau PET clocksMarta Milà-Alomà, Duygu Tosun, Suzanne E Schindler, et al.
Alzheimer'S & Dementia : the Journal of the Alzheimer'S Association|July 12, 2022
Comparative analytical performance of multiple plasma Aβ42 and Aβ40 assays and their ability to predict positron emission tomography amyloid positivityStephen Zicha, Randall J Bateman, Leslie M Shaw, et al.
Annals of Neurology|June 20, 2025
Timing of Changes in Alzheimer's Disease Plasma Biomarkers as Assessed by Amyloid and Tau PET ClocksMarta Milà-Alomà, Duygu Tosun, Suzanne E Schindler, et al.
Pageof 54

Showing results (501-510 of 531) with videos related to

Sort By:
Pageof 54
Arthritis Care & Research|November 22, 2021
Impact of Distinct Therapies on Antibody Response to SARS-CoV-2 Vaccine in Systemic Lupus ErythematosusEmily F N Yuki, Eduardo F Borba, Sandra G Pasoto, et al.
Journal of Physical Activity & Health|June 8, 2023
No Associations Between Physical Activity and Immunogenicity in SARS-CoV-2 Seropositive Patients With Autoimmune Rheumatic Diseases Prior to and After VaccinationFabiana Infante Smaira, Bruna Caruso Mazzolani, Ítalo Ribeiro Lemes, et al.
Journal of Clinical Rheumatology : Practical Reports on Rheumatic & Musculoskeletal Diseases|March 4, 2025
Disease Safety, Immunogenicity, and Efficacy of Recombinant Herpes Zoster Vaccine (RZV or Shingrix) in Autoimmune Rheumatic Diseases: Launching a Randomized Phase 4 StudyLeonard V K Kupa, Ana Cristina Medeiros-Ribeiro, Nádia E Aikawa, et al.
Annals of the Rheumatic Diseases|February 9, 2022
Distinct impact of DMARD combination and monotherapy in immunogenicity of an inactivated SARS-CoV-2 vaccine in rheumatoid arthritisAna Cristina Medeiros-Ribeiro, Karina Rossi Bonfiglioli, Diogo Souza Domiciano, et al.
Rheumatology (Oxford, England)|October 19, 2021
Systemic autoimmune myopathies: a prospective phase 4 controlled trial of an inactivated virus vaccine against SARS-CoV-2Samuel K Shinjo, Fernando H C de Souza, Isabela B P Borges, et al.
Plos One|November 17, 2011
Immunogenicity and reactogenicity of 2009 influenza A (H1N1) inactivated monovalent non-adjuvanted vaccine in elderly and immunocompromised patientsJoão L Miraglia, Edson Abdala, Paulo M Hoff, et al.
Journal of Applied Physiology (Bethesda, Md. : 1985)|February 10, 2022
Effect of an exercise bout before the booster dose of an inactivated SARS-CoV-2 vaccine on immunogenicity in immunocompromised patientsBruno Gualano, Carla G S Saad, Sofia M Sieczkowska, et al.
Medrxiv : the Preprint Server for Health Sciences|November 22, 2024
Timing of changes in Alzheimer's disease plasma biomarkers as assessed by amyloid and tau PET clocksMarta Milà-Alomà, Duygu Tosun, Suzanne E Schindler, et al.
Alzheimer'S & Dementia : the Journal of the Alzheimer'S Association|July 12, 2022
Comparative analytical performance of multiple plasma Aβ42 and Aβ40 assays and their ability to predict positron emission tomography amyloid positivityStephen Zicha, Randall J Bateman, Leslie M Shaw, et al.
Annals of Neurology|June 20, 2025
Timing of Changes in Alzheimer's Disease Plasma Biomarkers as Assessed by Amyloid and Tau PET ClocksMarta Milà-Alomà, Duygu Tosun, Suzanne E Schindler, et al.
Pageof 54